Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II single-arm study of ilparomlimab + tuvonralimab + lenvatinib in unresectable recurrent or metastatic mesothelioma
ChiCTR2500103457Phase 2Not yet recruiting
- Sponsor
- Zhejiang Cancer Hospital
- Start
- May 2025
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of AK127, tuvonralimab and lenvatinib in mesothelioma, sponsored by Zhejiang Cancer Hospital. Primary endpoint: Progression-free survival. Planned start May 2025; status: not yet recruiting.
02
Drugs
AK127tuvonralimablenvatinib
03
Conditions
mesothelioma
Beyond the preview
Go deeper on ChiCTR2500103457.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500103457.